Abstract 430P
Background
Teenagers and young adults (age 15-29) are increasingly the focus of cancer care in India. Young persons from rural western Madhya Pradesh, a resource crunch area, need provided support, and a care pathway to ensure optimal results in the treatment of cancer.
Methods
Disease characteristics of TYA patients over (30 months) from 2018-thru 2020 were analyzed. Abandonment defined as. Failure to start / complete treatment was quantified, and the cancers were documented by the Birch classification. Early deaths (within 30 days) and trends to completion of therapy were documented. Telephonic tracing of patients, escorting them to hospital, providing accommodation, food caregiver support. Since Feb 2019, the state sponsored Insurance scheme Ayushman Bharat provided TYAs access to cancer care.
Results
Two hundred and forty six cancer patients’ records in the age group 15-29 years were. analysed in a retrospective study. Median age 23 years; M: F 166: 80. Diseases were classified by the Birch Classification: Leukemias 84; Lymphomas. 45; Brain 6; Bone tumors 55; Soft tissue tumors 6; Germ Cell tumors 19; Carcinoma 30; Miscellaneous 1; Twenty two (9%) abandoned treatment. 65 (26%) alive after completed therapy; Early deaths occurred in 56 (23%); as of 30 June 2020, 103 (41%) are alive on treatment.
Conclusions
Early deaths occurred on account of poor nutrition; delayed diagnosis; toxicity of therapy.TYAcan Foundation provided diagnostic, treatment and accommodation support; mitigating early morbidity and mortality; tracking young persons to reduce abandonment. Early trends indicate that the government Ayushman Scheme and the social entrepreneurship of TYAcan together helped establish a viable care pathway for young cancer patients to achieve to survival rates.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Medical Oncology, Sri Aurobindo Institute of Medical sciences.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
348P - Anti-VEGF inhibitors and renal safety in onco-nephrology consortium: Urinary protein/creatinine ratio (VERSiON UP study)
Presenter: Michio Nakamura
Session: e-Poster Display Session
349P - Proteinuria in patients treated with ramcirumab increases the risk of renal dysfunction
Presenter: Kenta Hayashino
Session: e-Poster Display Session
350P - Rheumatologic immune related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy: A Western Australia experience
Presenter: Azim Khan
Session: e-Poster Display Session
351P - Valvular heart diseases in patients treated for breast cancer
Presenter: Ekaterina Kushnareva
Session: e-Poster Display Session
352P - Reproductive system disorders following chemotherapy in patients with breast cancer in Yogyakarta, Indonesia
Presenter: Irfan Haris
Session: e-Poster Display Session
353P - Survey for geriatric assessment in practising oncologists in India
Presenter: Vikas Talreja
Session: e-Poster Display Session
354P - Knowledge, perception, and attitude of oncology-related healthcare providers on complementary and alternative medicine (CAM)
Presenter: Chih Kiang Tan
Session: e-Poster Display Session
355P - Impact of comorbidities and rurality on treatment commencement, completion and outcomes, and health related quality of life, for geriatric oncology patients: Preliminary findings from a regional Australian study
Presenter: Mathew George
Session: e-Poster Display Session
357P - Comparison between immunotherapy and chemotherapy as neoadjuvant setting in resectable non-small cell lung cancer: A systematic review and meta-analysis of prospective trials
Presenter: Chao Zhang
Session: e-Poster Display Session
358P - Adjuvant tyrosine kinase inhibitors in non-squamous non-small cell lung cancer with EGFR driver mutations: An updated meta-analysis of randomized trials
Presenter: Joanmarie Balolong-Garcia
Session: e-Poster Display Session